survival trends and long-term toxicity in pediatric patients with osteosarcoma生存的趋势和儿童骨肉瘤患者的长期毒性.pdfVIP

Hindawi Publishing Corporation Sarcoma Volume 2012, Article ID 636405, 5 pages doi:10.1155/2012/636405 Clinical Study Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma Melanie M. Hagleitner,1 Eveline S. J. M. de Bont,2 and D. Maroeska W. M. te Loo1 1 Department of Pediatric Hematology and Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 2 Department of Pediatric Hematology and Oncology, University Medical Centre Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands Correspondence should be addressed to Melanie M. Hagleitner, mm.hagleitner@cukz.umcn.nl Received 4 July 2012; Revised 23 October 2012; Accepted 2 November 2012 Academic Editor: Norman Jaffe Copyright © 2012 Melanie M. Hagleitner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. This study was conducted to investigate the clinical characteristics and treatment results of osteosarcoma in pediatric patients during the past 30 years. Trends in survival rates and long-term toxicity were analyzed. Procedure. 130 pediatric patients under the age of 20 years with primary localized or metastatic high-grade osteosarcoma were analyzed regarding demographic, treatment-related variables, long-term toxicity, and survival data. Results. Comparison of the different time periods of treatment showed that the 5-year OS improved from 58.6% for children diagnosed during 1979–1983 to 78.6% for those diagnosed during 2003–2008 (P = 0.13). Interestingly, the basic treatment agents including cisplatin, doxorubicin, and methot